Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ecka Health vs RxSpan MD

By GLP-1 ScorecardUpdated

Ecka Health
Site position #376

Lower score

RxSpan MD
Site position #4

Higher score

Score comparison

RxSpan MD has the higher recorded score — 84.3/100 to 59.3/100.

RxSpan MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.

Before you choose

RxSpan MD does not publish a semaglutide price, so its RxSpan MD review sets out what it does disclose, while the Ecka Health review explains the conditions attached to Ecka Health's figure. The semaglutide cost page compares published rates across the field. Ask RxSpan MD for a written total before treating either one as the cheaper choice.

If neither one fits, BiltRx vs Ecka Health and Eclipse Medical Wellness vs RxSpan MD compare each of them with another graded program, and the list of alternatives to Ecka Health ranks the programs closest to Ecka Health on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueRxSpan MD +41
45
86
Dose & formulationRxSpan MD +12
77
89
Clinical oversightRxSpan MD +20
68
88
Labs & monitoringRxSpan MD +32
51
83
FulfillmentRxSpan MD +24
65
89
Contract termsRxSpan MD +8
45
53
Ecka Health · top barRxSpan MD · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricEcka HealthRxSpan MD
WeighScore59.3/10084.3/100
GradeCB
Site position#376#4
SemaglutideAdvertised from $99/mo; pricing shown during the online visit, plan length not publishedCurrent compounded quote unconfirmed
TirzepatideAdvertised from $199/mo; pricing shown during the online visit, plan length not publishedCurrent compounded quote unconfirmed
CoverageAdvertised as nationwide; no state listConfirm treatment availability during intake
Brand-name accessYesYes
Oral / sublingualNot confirmedNot confirmed
Ecka Health

Site position #376 · C

Strengths

  • Names its prescribing physicians
  • Offers brand Zepbound alongside compounded options
  • Shows a LegitScript seal

What to consider

  • The real price appears only during the online visit
  • No legal company name or address is published
  • The semaglutide page never says whether the drug is compounded or brand, and the tirzepatide page still shows template placeholder text
  • Approved orders are final and not refundable
RxSpan MD

Site position #4 · B

Strengths

  • Current public catalog lists Ozempic, Wegovy, Mounjaro and Zepbound
  • Public terms describe independent healthcare providers
  • Homepage describes messaging and care-team appointments

What to consider

  • Homepage advertises compounded plans that the current catalog did not substantiate
  • Current oral GLP-1 availability is unconfirmed
  • Prior compounded prices are not a current quote; selected dose, supply, pharmacy and fee inclusions need confirmation
  • Public terms do not establish unused prepaid-treatment refund amounts

Featured provider

RxSpan MD

RxSpan MD scores 84.3/100 (B). RxSpan MD's live catalog lists brand-name GLP-1 drugs, while its homepage also advertises compounded plans; confirm the actual product and total price before enrolling.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard